Bayer Loses Patent Fight Over Cancer Drug

By Admin
Pharmaceutical giant Bayer has lost its legal fight to overturn the Indian governments decision to allow Natco Pharma to produce its cancer drug Nexav...

 

Pharmaceutical giant Bayer has lost its legal fight to overturn the Indian government’s decision to allow Natco Pharma to produce its cancer drug Nexavar under compulsory licence.

The Intellectual Property Appellate Board (IPAB) in Chennai upheld the landmark decision made last March by the comptroller of patents citing the high cost of the medication.

Nexavar is used in the treatment of liver and kidney cancer and was sold by Bayer for Rs.280,000 ($5,100) per month while Natco is selling the drug for only Rs. 6,840 ($125) a month.

Natco will pay Bayer, Germany’s largest pharmaceutical company, a seven percent royalty rate on all the drugs they sell. The percentage was raised from six percent royalties by the IPAB.

“The challenges faced by the Indian healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India’s essential drug list are not patented,” said Bayer. The company has stated that they intend to take the case to the Indian high court.

The compulsory license is recognised by the World Trade Organisation and is a tool used by governments to allow a company to manufacture a patented drug, without the consent of the innovator company.

Under the global Trade-Related Aspects of Intellectual Property Rights agreement, countries can issue these licences on drugs that are deemed unaffordable to a large section of their populations.

Charities working in India were relieved by the decision. Medecins sans Frontieres said, “The decision confirms that the Indian patent office is able to use all the means legally at its disposal to check the abuse of patents and open up access to affordable versions of patented medicines.”

Share

Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI

AI & ML

Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI